Last week, the DEA moved to place five little-known psychedelic compounds — 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT — into Schedule I of the Controlled Substances Act. It’s the agency’s second attempt at this exact scheduling action; it withdrew an earlier version in 2022 after pushback from researchers and legal advocates.
MAPS opposes this proposal.
These five lesser known psychedelic substances — 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT — don’t belong in Schedule I. At MAPS, we don’t advocate for adding more drugs to the highest level of the Controlled Substances Act. Schedule I does two things at once: it shuts down the research that could tell us what benefits, if any, these drugs have, and it turns personal use of them into a criminal matter. DEA’s own record fails to show a level of public harm that justifies either one. We’d rather see these substances stay researchable and see the people who use them treated outside the criminal system, not funneled into it by default.
This move follows actions by the DEA to reschedule other little-known psychedelics, DOI, and DOC into Schedule I. The agency continues to inexplicably repeat the mistakes of the last fifty years by leading with criminalization instead of the research, education, and harm reduction that actually keep people and communities safe.
— Ismail L. Ali, J.D.
Co-Executive Director of MAPS

